ARTCLINE Establishes Scientific Advisory Board with Leading Experts from Nephrology, Intensive Care and Transfusion Medicine

ARTCLINE Establishes Scientific Advisory Board with Leading Experts from Nephrology, Intensive Care and Transfusion Medicine

• ARTCLINE brings interdisciplinary expertise on board in new scientific advisory board
• Scientific and strategic support for the development of ARTICE^® therapy in the treatment of septic shock and immune paralysis
• ReActIF-ICE study currently recruiting patients at 20 intensive care units in Germany

Rostock, Germany, May 22, 2025 – ARTCLINE, a biomedical company focused on the development of new immune cell therapies for the treatment of septic shock, today announced the formation of its Scientific Advisory Board. This interdisciplinary panel will support the company with scientific expertise and strategic advice.

“The establishment of our scientific advisory board with internationally renowned experts underscores the importance of our pioneering ARTICE^® therapy for the treatment of sepsis-induced immune failure and enables us to scientifically support its further development and application as it progresses toward market entry,” said Dirk Hessel, Managing Director of ARTCLINE GmbH. Dr. Jens Altrichter, Managing Director and founder of ARTCLINE GmbH, added: “With their extensive expertise in intensive care medicine, transfusion medicine, nephrology, and cell therapy, the members of the advisory board support the scientific development of our immune cell therapy and represent an important link between research and clinical application. This strategic collaboration will help us to add an important new treatment option to the long-term standard of care for septic shock. I am very grateful to the members of the advisory board for their support in this endeavor."

The members of the scientific advisory board are:

• Prof. Dr. med. Christian Bode (MD), Bonn
  Deputy Director of the Department of Anesthesiology and Intensive Care Medicine and Senior Physician at the University Hospital Bonn. Expert in immune mechanisms in sepsis, acute lung failure (ARDS), and severe inflammatory reactions (SIRS). His research focuses in particular on the interaction between immunopathogenesis and organ dysfunction in critically ill patients and the use of extracorporeal blood purification procedures in septic shock.
   
• Prof. Dr. med. Andreas Kribben (MD), Essen
  Director of the Department of Nephrology at Essen University Hospital and specialist in transplant medicine and extracorporeal therapies. The former President of the German Society of Nephrology (DGfN) and member of international professional associations has extensive scientific and clinical experience with innovative treatment options for patients with organ failure.
   
• Prof. Dr. rer . nat. Dr. med. h.c. Siegfried Neumann, Darmstadt
  Honorary professor at Technical University of Darmstadt and for many years scientific advisor for technology transfer and innovation management. As former head of the immunochemistry research departments in preclinical and diagnostic research at Merck KGaA and as consultant to the German Federal Ministry of Education and Research (BMBF) in research programs for biotechnology, molecular diagnostics, and medical technology, he has validated numerous development projects.
   
• Prof. Dr. med. Thomas Thiele (MD), Greifswald
  Head of the Institute for Transfusion Medicine at University Medical Center Greifswald and specialist in transfusion medicine and hemostaseology. His research focuses on coagulation disorders, particularly related to infections and drug therapies.
   

Clinical evaluation in ongoing ReActIF-ICE study

With over 200,000 cases annually in Germany alone and estimated costs of €7.7 billion per year, sepsis is one of the greatest challenges for the healthcare system. These figures demonstrate the urgent need for a new, targeted therapy. With its innovative ARTICE^® treatment, ARTCLINE is pursuing an immunomodulatory treatment strategy for patients with septic shock. The extracorporeal therapy uses immune cells from healthy donors to relieve and regenerate the patient’s dysregulated immune system. The ReActIF-ICE study is currently evaluating the therapy in 20 leading intensive care centers. The study has recruited more than 90 patients to date, while a total of 140 patients are to be included by the end of 2025. In parallel to this study, preparations for market launch are already underway.

About ARTCLINE GmbH

ARTCLINE GmbH was founded as a spin-off from the University of Rostock. The company is developing innovative diagnostic and therapeutic procedures for intensive care medicine. The focus is on a novel immune cell-based extracorporeal procedure for the treatment of septic shock – one of the major challenges for global health systems.

Developed by immunologists and dialysis specialists, the ARTICE^® therapy uses immune cells from healthy donors to temporarily take over some of the functions of the patient's impaired immune system and reactivate it.

For more information, visit www.artcline.de, follow us on LinkedIn or contact us at info@artcline.de.

Contact:       
ARTCLINE GmbH     
Dirk Hessel, Managing Director     
dirk.hessel@artcline.de     

Media inquiries:
MC Services AG
Eva Bauer / Julia von Hummel
Phone: +49-89-210228-0
artcline@mc-services.eu